Novartis reverses course on Swiss OTC plant that was to be closed

Eric Palmer Novartis is doing a complete U-turn on an OTC plant in Switzerland that 18 months ago was going to get the old heave-ho along with the people who worked there. Now the ...

SEC probes former Dendreon CEO’s stock sales

Tracy Staton The Securities and Exchange Commission's insider trading team has Dendreon ($ DNDN) under a microscope. The agency has launched a civil investigation into stock trades ...

Celladon’s gene therapy for heart failure takes spotlight in the U.K.

John Carroll San Diego-based Celladon has made a big splash in the U.K. British scientists are playing a prominent role in a pair of clinical trials of Celladon's Mydicar, a gene ...

Ex-Genzyme chief Termeer joins board at Cambridge biotech

Tracy Staton Moderna Therapeutics has scored another coup. The biotech, which struck a major development deal with AstraZeneca ($ AZN) just months after it shed stealth status, has ...

Johnson & Johnson allies with biotech startup on HIV drug in China

Ryan McBride The biopharma startup Ascletis has snagged exclusive rights from Johnson & Johnson's ($ JNJ) Janssen for an experimental HIV protease inhibitor for the China ...

Pfizer cuts forecast as Q1 sales fall $550M short of estimates

Tracy Staton Like many of its rivals, Pfizer ($ PFE) reported a dip in quarterly sales: 9%, to be exact, to $ 13.5 billion. But worse for Pfizer, the decline was bigger than analysts ...

Biotech legend Termeer joins the board at Moderna

John Carroll Cambridge, MA-based Moderna Therapeutics has scored another coup. The biotech, which struck a major development deal with AstraZeneca ($ AZN) just months after it shed ...

Merck wins bellwether Fosamax femur-fracture trial

Tracy Staton The jury in the latest Fosamax trial has spoken, and it spoke for Merck ($ MRK). In a federal court in New Jersey, the panel determined that plaintiff Bernadette Glynn's ...

Biotech upstart joins Big Pharma cast on high-profile “breakthrough” stage

John Carroll   Up until now the FDA has reserved its new "breakthrough" designation for a Who's Who in drug development, with high-profile companies like J&J, ...

Regeneron execs score $140M payday as Eylea mints money

Tracy Staton How much is a wildly successful drug worth? For Regeneron’s top executives, the answer is $ 140 million. With its vision-loss drug beating all sales expectations ...

Aveo shares plunge after FDA raises fears of tivozanib rejection

John Carroll   Regulators at the FDA have weighed the data for Aveo's tivozanib, raising a simple question that could prove vexing for the biotech: Should another clinical ...

Regado gambles on $75M IPO to pay pricey PhIII tab

John Carroll Late last year Regado Biosciences came up with a big $ 51 million round that served as a kind of down payment on a planned $ 120 million study of its lead therapy–an ...
Page 1 of 1712345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS